Fusilev
Fusilev (levoleucovorin) is a folate analog and the pharmacologically active L-isomer of racemic leucovorin. It is used in oncology as a rescue agent after high-dose methotrexate therapy to protect healthy cells, as an antidote to folic acid antagonist overdose, and to enhance the therapeutic effects of 5-fluorouracil in colorectal cancer.
Dosage by Body Weight
Dosing of Fusilev is highly individualized and must be supervised by an oncologist. It is administered intravenously and is typically dosed based on Body Surface Area (BSA) in mg/m² rather than body weight alone, often adjusted in response to serum methotrexate concentration monitoring.
- Body Weight
- Below 5 kg
- Dose
- Individualized by oncologist
- Frequency
- Based on clinical protocol
- Tracking Notes
- Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone.
- Body Weight
- 5-7 kg
- Dose
- Individualized by oncologist
- Frequency
- Based on clinical protocol
- Tracking Notes
- Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone.
- Body Weight
- 8-10 kg
- Dose
- Individualized by oncologist
- Frequency
- Based on clinical protocol
- Tracking Notes
- Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone.
- Body Weight
- 11-15 kg
- Dose
- Individualized by oncologist
- Frequency
- Based on clinical protocol
- Tracking Notes
- Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone.
- Body Weight
- 16-20 kg
- Dose
- Individualized by oncologist
- Frequency
- Based on clinical protocol
- Tracking Notes
- Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Individualized by oncologist | Based on clinical protocol | Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone. |
| 5-7 kg | Individualized by oncologist | Based on clinical protocol | Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone. |
| 8-10 kg | Individualized by oncologist | Based on clinical protocol | Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone. |
| 11-15 kg | Individualized by oncologist | Based on clinical protocol | Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone. |
| 16-20 kg | Individualized by oncologist | Based on clinical protocol | Dosed according to body surface area (BSA) and blood methotrexate levels. Not routinely dosed by body weight alone. |
Formulation
Purpose
Used to prevent or rescue normal cells from the toxic effects of high-dose methotrexate therapy in patients with osteosarcoma, to treat accidental overdose of folic acid antagonists, and in combination with 5-fluorouracil to treat patients with metastatic colorectal cancer.
Generic Name
LevoleucovorinScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.